Feasibility, safety and tolerability of intradialytic creatine supplementation in hemodialysis: A double-blind, randomized, placebo-controlled pilot study
PLOS One · 05.08.2026 · 21 (8) · e0354883
DOI: 10.1371/journal.pone.0354883 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, online erschienen am 05.08.2026. Verfasst von Caecilia S E Doorenbos und 19 weiteren Autor:innen. Beteiligte Einrichtung: University of Groningen, Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Renal Dialysis, Creatine, Dietary Supplements. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Crearene AG.
Abstract (Originalsprache)
Background
Patients receiving hemodialysis are at risk of creatine deficiency due to impaired endogenous synthesis and losses during dialysis. Creatine deficiency is associated with lower health-related quality of life and higher mortality. We investigated the feasibility, tolerability and safety of intradialytic creatine supplementation during hemodialysis.
Methods
In this double-blind, randomized, placebo-controlled pilot study (ClinicalTrials.gov ID: NCT05148208), 16 hemodialysis patients were included into four sequentially initiated groups, with each group receiving a fixed creatine concentration in the dialysate (0.5 mmol/L, 1.0 mmol/L, 1.5 mmol/L and 2.0 mmol/L, respectively), with block randomization in a 3:1 ratio (creatine:placebo) per group. Dropouts were replaced. Intra-dialytic creatine was administered during a 6-week period. Primary outcomes were changes in pre-dialytic intra-erythrocytic and plasma creatine concentrations, which were analyzed with linear mixed models.
Results
16 hemodialysis patients (aged 27–78 years, 9 female) completed the study. Creatine supplementation was generally well tolerated. One patient receiving 1.5 mmol/L creatine dropped out due to a potential side effect. No serious adverse events occurred. The median (minimum-maximum) baseline pre-dialytic intra-erythrocytic and plasma creatine concentrations were 963 (407–1822) and 35 (13–287) µmol/L, respectively. At 6 weeks, the changes in pre-dialytic intra-erythrocytic creatine concentration compared to placebo (95% CI) were +399 (−269, 1066), + 685 (+17, + 1352), + 1146 (+431, + 1766) and +1098 (+431, + 1766) µmol/L for the increasing dosage treatment groups respectively (overall treatment effect p < 0.001). The changes in pre-dialytic plasma creatine concentration compared to placebo were −16 (−301, + 270), + 21 (−264, + 307), + 119 (−264, + 307) and +163 (−122, + 449) µmol/L for the increasing dosage treatment groups respectively (overall treatment effect p = 0.002).
Conclusion
Intra-dialytic creatine supplementation is a feasible, safe, well-tolerated method to increase circulating creatine concentrations in patients treated with hemodialysis. These findings support the rationale for a larger randomized controlled trial to investigate its potential to improve health-related quality of life and reduce mortality risk in this population. Trial Registration: ClinicalTrials.gov ID NCT05148208, date of first registration 08/12/2021
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Groningen, Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, Groningen, The Netherlands.
- University of Groningen, Department of Laboratory Medicine, University Medical Center Groningen, Groningen, The Netherlands.
- Dialysis Center Groningen, Groningen, The Netherlands.
- University of Groningen, Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.
- Department of Biology, ETH Zurich, Zurich, Switzerland.
ORCID-Profile: Caecilia S E Doorenbos, Daan Kremer, Dion Groothof, Stephan J L Bakker
Förderung
- Crearene AG
Zitieren
APA
Doorenbos, C. S. E., van der Veen, Y., Post, A., Jonker, J., Knobbe, T. J., Kremer, D., Groothof, D., Heiner-Fokkema, M. R., Koops, C. A., Bijsterveld, K., Marsman, E., Hazenberg, I. T., Manson, N. A., Appeldoorn, T. Y. J., Boersma, H. H., Dekkers, B. G. J., Touw, D. J., Wallimann, T., Franssen, C. F. M., & Bakker, S. J. L. (2026). Feasibility, safety and tolerability of intradialytic creatine supplementation in hemodialysis: A double-blind, randomized, placebo-controlled pilot study. PLOS One, 21(8), e0354883. https://doi.org/10.1371/journal.pone.0354883
Vancouver
Doorenbos CSE, van der Veen Y, Post A, Jonker J, Knobbe TJ, Kremer D, et al. Feasibility, safety and tolerability of intradialytic creatine supplementation in hemodialysis: A double-blind, randomized, placebo-controlled pilot study. PLOS One. 2026;21(8):e0354883. doi:10.1371/journal.pone.0354883
BibTeX
@article{Doorenbos2026,
author = {Doorenbos, Caecilia S E and van der Veen, Yvonne and Post, Adrian and Jonker, Jip and Knobbe, Tim J and Kremer, Daan and Groothof, Dion and Heiner-Fokkema, M Rebecca and Koops, Christa A and Bijsterveld, Klaas and Marsman, Erik and Hazenberg, Ietje T and Manson, Nienke A and Appeldoorn, Theo Y J and Boersma, Hendrikus H and Dekkers, Bart G J and Touw, Daan J and Wallimann, Theo and Franssen, Casper F M and Bakker, Stephan J L},
title = {Feasibility, safety and tolerability of intradialytic creatine supplementation in hemodialysis: A double-blind, randomized, placebo-controlled pilot study},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {8},
pages = {e0354883},
doi = {10.1371/journal.pone.0354883}
}
EUVIMED